GGrantIndex
← Leaderboards

Lisa A Carey

Univ Of North Carolina Chapel Hill

$11,034,788
Attributed
$13,523,111
Total exposure
17
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,788,811 · 18

By mechanism

P50$10,665,289 · 5
UG1$3,467,209 · 1
R01$3,398,108 · 1
U10$2,766,626 · 1
P30$1,266,920 · 4
U01$639,882 · 1

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchFundingClinical TrialsProgramsTranslational ResearchFacultyLeadershipMalignant Breast NeoplasmDesignWomanGenomicsGrantNorth CarolinaResearch PersonnelBasic ScienceMalignant NeoplasmsCancer CenterDisciplinePublishingSuccessBreastInvestmentsAnticancer ResearchAward

Grant awards (72)

SPORE in Breast Cancer$2,348,589
P50 · FY2025 · CA
Elucidating the molecular mechanisms of metastasis organ tropism$639,882
U01 · FY2025 · CA
Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBC$596,748
R01 · FY2025 · CA · contact PI
UNC Lead Academic Participating Site$454,679
UG1 · FY2025 · CA · contact PI
Career Enhancement Program$76,135
P50 · FY2025 · CA · contact PI
SPORE in Breast Cancer$2,268,690
P50 · FY2024 · CA
UNC Lead Academic Participating Site$454,681
UG1 · FY2024 · CA · contact PI
Career Enhancement Program$74,640
P50 · FY2024 · CA · contact PI
Breast Cancer Research Program$42,152
P30 · FY2024 · CA · contact PI
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms$545,651
R01 · FY2023 · CA · contact PI
UNC Lead Academic Participating Site$504,995
UG1 · FY2023 · CA · contact PI
Breast Cancer Research Program$46,834
P30 · FY2023 · CA · contact PI
SPORE in Breast Cancer$2,324,485
P50 · FY2022 · CA
UNC Lead Academic Participating Site$504,963
UG1 · FY2022 · CA · contact PI
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms$485,168
R01 · FY2022 · CA · contact PI
Career Enhancement Program$81,026
P50 · FY2022 · CA · contact PI
Breast Cancer Research Program$46,834
P30 · FY2022 · CA · contact PI
SPORE in Breast Cancer$2,323,936
P50 · FY2021 · CA
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms$542,931
R01 · FY2021 · CA · contact PI
UNC Lead Academic Participating Site$537,489
UG1 · FY2021 · CA · contact PI
Career Enhancement Program$81,007
P50 · FY2021 · CA · contact PI
Breast Cancer Research Program$46,834
P30 · FY2021 · CA · contact PI
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms$616,954
R01 · FY2020 · CA · contact PI
UNC Lead Academic Participating Site$505,201
UG1 · FY2020 · CA · contact PI
Career Enhancement Program$79,948
P50 · FY2020 · CA · contact PI
Breast Cancer Research Program (Program 7)$39,437
P30 · FY2020 · CA · contact PI
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms$610,656
R01 · FY2019 · CA · contact PI
UNC Lead Academic Participating Site$505,201
UG1 · FY2019 · CA · contact PI
Career Enhancement Program$258,168
P50 · FY2019 · CA · contact PI
Breast Cancer Research Program (Program 7)$38,225
P30 · FY2019 · CA · contact PI
NCTN Lead Academic Participating Sites Application$623,046
U10 · FY2018 · CA · contact PI
Career Enhancement Program$87,144
P50 · FY2018 · CA · contact PI
Breast Cancer Research Program (Program 7)$39,435
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (Program 7)$2,968
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (Program 7)$2,101
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (Program 7)$1,366
P30 · FY2018 · CA · contact PI
NCTN Lead Academic Participating Sites Application$454,315
U10 · FY2017 · CA · contact PI
Breast Cancer Research Program (Program 7)$38,686
P30 · FY2017 · CA · contact PI
NCTN Lead Academic Participating Sites Application$474,318
U10 · FY2016 · CA · contact PI
Breast Cancer Research Program (Program 7)$38,921
P30 · FY2016 · CA · contact PI
NCTN Lead Academic Participating Sites Application$591,897
U10 · FY2015 · CA · contact PI
Breast Cancer Research$173,211
P30 · FY2015 · CA · contact PI
NCTN Lead Academic Participating Sites Application$623,050
U10 · FY2014 · CA · contact PI
Breast Cancer Research$163,380
P30 · FY2014 · CA · contact PI
Breast Cancer Research$169,861
P30 · FY2013 · CA · contact PI
Academic Training in Oncology at the University of North Carolina at Chapel Hill$255,067
T32 · FY2012 · CA · contact PI
Breast Cancer Research$186,853
P30 · FY2012 · CA · contact PI
Academic Training in Oncology at the University of North Carolina at Chapel Hill$70,772
T32 · FY2012 · CA · contact PI
Breast Cancer Research$2,552
P30 · FY2012 · CA · contact PI
Academic Training in Oncology at the University of North Carolina at Chapel Hill$220,020
T32 · FY2011 · CA · contact PI
Breast Cancer Research$187,270
P30 · FY2011 · CA · contact PI
Developmental Research Program$141,030
P50 · FY2010 · CA · contact PI
Developmental Research Program$141,210
P50 · FY2009 · CA · contact PI
Developmental Research Program$141,368
P50 · FY2008 · CA · contact PI
Developmental Research Program$137,983
P50 · FY2007 · CA · contact PI
LCCC 0403: PHASE II CETUXIMAB ALONE AND IN COMBINATION WITH CARBOPLATIN$750
M01 · FY2007 · RR · contact PI
Developmental Research Program$99,930
P50 · FY2006 · CA · contact PI
LCCC 9818: STAGE IIB, STAGE IIIA/B STAGE IV BREAST CANCER$1,239
M01 · FY2006 · RR · contact PI
LCCC 9818: STAGE IIB, STAGE IIIA/B STAGE IV BREAST CANCER$21,363
M01 · FY2005 · RR
LCCC 9818: Stage IIB, Stage IIIA/B Stage IV Breast Cancer$15,566
M01 · FY2004 · RR
CORRELATION OF MARKER WITH RESPONSE TO CHEMOTHERAPY$0
P50 · FY2002 · CA
CORRELATION OF MARKER WITH RESPONSE TO CHEMOTHERAPY$0
P50 · FY2001 · CA
DOXORUBICIN &CYCLOPHOSPHAMIDE &PACLITAXEL W/ HERCEPTIN$0
M01 · FY2000 · RR
TAMOXIFEN &RALOXIFENE FOR PREVENTTION OF BREAST CANCER$0
M01 · FY2000 · RR
TAMOXIFEN &RALOXIFENE FOR PREVENTTION OF BREAST CANCER$0
M01 · FY2000 · RR
TAMOXIFEN &RALOXIFENE FOR PREVENTTION OF BREAST CANCER$0
M01 · FY2000 · RR
MOLECULAR MARKERS W/ RESPONSE TO CHEMOTHERAPY IN BREAST CA$0
M01 · FY2000 · RR
MOLECULAR MARKERS W/ RESPONSE TO CHEMOTHERAPY IN BREAST CA$0
M01 · FY2000 · RR
MOLECULAR MARKERS W/ RESPONSE TO CHEMOTHERAPY IN BREAST CA$0
M01 · FY2000 · RR
MOLECULAR MARKERS W/ RESPONSE TO CHEMOTHERAPY IN BREAST CA$0
M01 · FY2000 · RR
DOXORUBICIN &CYCLOPHOSPHAMIDE &PACLITAXEL W/ HERCEPTIN$0
M01 · FY2000 · RR
DOXORUBICIN &CYCLOPHOSPHAMIDE &PACLITAXEL W/ HERCEPTIN$0
M01 · FY2000 · RR